Patient Square Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001819257

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q4 2025 · 28 positions · Total reported value $467.13M · Top-10 concentration 77.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 69.0% · 6 new · 8 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2025 13F filing, Patient Square Capital LP disclosed 28 equity positions with a combined reported value of $467.13M. The filing implies a focused portfolio: its ten largest positions account for 77.5% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were ROIV ($177.20M), INSM ($46.47M), MIRM ($23.59M). By sector, the heaviest allocations are Health Care 94.2%, Industrials 3.1%. Versus the prior quarter, allocation shifted toward Health Care (+1.1pp) and away from Industrials (-0.8pp).

Versus the prior quarter, Patient Square Capital LP opened 6 new positions, trimmed 8 and fully exited 6, a turnover rate of 69.0% of positions. The portfolio's overlap with the prior quarter was 58% of names.

The largest new positions opened in Q4 2025 were ONC ($21.06M), TERN ($12.93M), COGT ($11.27M).

Of the 6 positions fully exited versus the prior quarter, the largest were CDTX ($11.59M), AGIO ($5.37M), QURE ($4.38M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • ONC BEONE MEDICINES LTD · $21.06M
  • TERN TERNS PHARMACEUTICALS INC · $12.93M
  • COGT COGENT BIOSCIENCES INC · $11.27M
  • DBVT DBV Technologies SA · $6.88M
  • XENE XENON PHARMACEUTICALS INC · $6.12M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC · $6.10M
  • SYRE SPYRE THERAPEUTICS INC · $4.91M
  • RCUS ARCUS BIOSCIENCES INC · $4.05M

Fully Exited (vs previous quarter)

  • CDTX CIDARA THERAPEUTICS INC · prev qtr: $11.59M
  • AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $5.37M
  • QURE UNIQURE NV · prev qtr: $4.38M
  • NRIX NURIX THERAPEUTICS INC · prev qtr: $4.04M
  • GERN GERON CORP · prev qtr: $1.16M

Insider Transactions (Form 4)

Latest Patient Square Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Patient Square Capital LP is a Menlo Park, CA-based investment firm founded by David Goel and Stephen Mandel Jr. with approximately $17.5 billion in assets under management.

Investment Approach

They employ a long-term, concentrated investment strategy focusing on high-quality companies with strong competitive advantages.

Asset Classes

Primarily invests in US equities, as evidenced by their SEC Form 13F filings.

Notable Facts

Founded in 2016, known for activist investment style, sometimes taking significant positions in companies and advocating for changes.

Key People

Founded by David Goel and Stephen Mandel Jr. (co-founder of Lone Pine Capital).

For official disclosures, refer to the firm's SEC filings.

Sector Allocation

Health Care 94.2%
Other 2.8%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 8.17M $177.20M 37.93%
37.93%
Reduce
2 267.00K $46.47M 9.95%
9.95%
Reduce
3 298.68K $23.59M 5.05%
5.05%
Add
4 26.00K $21.86M 4.68%
4.68%
Add
5 69.31K $21.06M 4.51%
4.51%
New
6 130.00K $17.53M 3.75%
3.75%
Reduce
7 542.70K $15.06M 3.22%
3.22%
Add
8 780.00K $14.25M 3.05%
3.05%
Reduce
9 320.00K $12.93M 2.77%
2.77%
New
10 120.00K $11.97M 2.56%
2.56%
Add
11 317.37K $11.27M 2.41%
2.41%
New
12 139.00K $10.82M 2.31%
2.31%
Add
13 227.00K $7.83M 1.68%
1.68%
Reduce
14 359.05K $6.88M 1.47%
1.47%
New
15 4.96M $6.80M 1.46%
1.46%
Add
16 150.00K $6.18M 1.32%
1.32%
Add
17 136.50K $6.12M 1.31%
1.31%
New
18 210.00K $6.10M 1.30%
1.30%
New
19 490.00K $5.95M 1.27%
1.27%
Reduce
20 74.00K $5.88M 1.26%
1.26%
Hold
21 311.97K $5.67M 1.21%
1.21%
Add
22 150.00K $4.91M 1.05%
1.05%
New
23 308.14K $4.75M 1.02%
1.02%
Add
24 127.00K $4.32M 0.93%
0.93%
Reduce
25 350.00K $4.23M 0.91%
0.91%
Add
26 170.00K $4.05M 0.87%
0.87%
New
27 1.13M $3.12M 0.67%
0.67%
Add
28 7.03K $344.52K 0.07%
0.07%
New

FAQ

What did Patient Square Capital LP buy in 2025-Q4?

In its 2025-Q4 13F filing, Patient Square Capital LP reported 28 equity positions worth $467.13M in aggregate; its largest disclosed positions were ROIV ($177.20M), INSM ($46.47M), MIRM ($23.59M).

How large is Patient Square Capital LP's portfolio?

Patient Square Capital LP reported $467.13M of long equity holdings across 28 positions as of 2025-Q4. Top-10 holdings account for 77.5% of reported value.

What is Patient Square Capital LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/patient-square-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →